Joint Press Release. Company will participate with bamboo.com in ------------------- issuing a joint press release regarding the relationship established through this Agreement. Each party shall agree on the form and content of such press release and will furnish its written acceptance of, or comments on, the proposed announcement within 48 hours of receipt of such proposed announcement; otherwise such proposed announcement will be deemed approved. Any other press announcement by either party regarding the subject matter of this Agreement will be subject to the other party's approval, which shall not be withheld or delayed unreasonably.
Joint Press Release. April XX, 2019 For Release: Draft B Refer to: Mark Taylor; firstname.lastname@example.org; (317) 276-5795 (Lilly Media) Kevin Hern; email@example.com; (317) 277-1838 (Lilly Investors) Leslie Ann Kerins; firstname.lastname@example.org; (858) 401-7900 (Avidity) Ian Stone; email@example.com; (619) 849-5388 (Avidity Media) Lilly and Avidity Biosciences Announce Licensing and Research Collaboration • Collaboration will utilize Avidity’s antibody-oligonucleotide conjugate (AOC) technology to pursue therapeutic targets initially focused on immunology and other indications • Avidity to receive an upfront payment of $20 million and an investment of $15 million • Avidity eligible to receive up to approximately $405 million per target in development and commercialization milestones, plus royalties INDIANAPOLIS, IN, LA JOLLA, CA — Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications. The companies will utilize Avidity’s proprietary Antibody-Oligonucleotide Conjugate (AOC™) technology platform to progress new therapeutic approaches toward clinical development and commercialization. AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease. “We are excited to expand our oligonucleotide research and development efforts through this strategic collaboration with Avidity,” said Andrew C. Adams, Ph.D., chief scientific officer for RNA therapeutics at Lilly. “Their expertise in studying the combination of monoclonal antibodies and oligonucleotide-based therapies represent a promising avenue of research toward development of the next generation of RNA based medicines” “This collaboration with Lilly provides an exceptional opportunity to leverage Avidity’s proprietary AOC platform in order to generate new therapeutic targets in disease areas that have been challenging to pursue using oligonucleotide-based approaches,” said Kent Hawryluk, Avidity’s chief business officer. “Lilly’s extensive research, development, regulatory, and commercial capabilities make them an ideal partner, and we look forward to a long and productive relationship.” Under the terms of the agreement, Avidity will receive an upfront payment of $20 million, as well as an...
Joint Press Release. The Claimants and Target may jointly issue a press release announcing the terms of this Agreement. If the Parties cannot agree on the language of a joint press release, or the timing of its issuance, either party may issue its own release provided that it is shared with the other Parties at least three business days prior to issuance, is consistent with the terms of this Agreement, and reflects the collaborative method in which the Parties resolved the Dispute.
Joint Press Release. The parties shall issue a joint press release announcing their relationship no later than sixty (60) days following the execution of this Agreement. This joint press release will include quotes from senior management members (title of Vice President or higher) of each company and will emphasize the RSA Security-enabled aspects of your Licensed Products. Notwithstanding the foregoing, the parties agree that any press, marketing or advertising releases or similar promotional materials, including on-line promotion, of either party that refer to the other party or the other party's products shall not be released or disseminated without the prior written approval of the other party.
Joint Press Release. No later than the first business day following execution of this Agreement, and subject to the conditions of this Agreement, Razorfish will issue the Joint Press Release with the Parent and the Purchaser and file with the SEC the Joint Press Release, under cover of Schedule 14D-9, indicating on the front of such Schedule 14D-9 that such filing contains pre-commencement communications.
Joint Press Release. On the date of the publication of the Pre-Announcement, ChemChina and Syngenta shall publish their respective press releases substantially in the form set forth in Annexes 3.4(i) and (ii), including the Syngenta Board’s support for, and its recommendation and support for acceptance of, the Offer.